CAMBRIDGE, Mass., May 14, 2007 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that the Company has initiated dosing of its Phase I study to evaluate the human safety, tolerability, bioavailability and pharmacokinetics of a subcutaneous formulation of M118, the Company's lead novel development candidate. M118 is a next-generation anticoagulant designed specifically for use in treating patients diagnosed with acute coronary syndromes (ACS). An IND for the subcutaneous formulation was submitted in April to and cleared by the Division of Cardiovascular and Renal Products within the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER).
